Arcutis Biotherapeutics (NASDAQ:ARQT) Posts Earnings Results, Beats Expectations By $0.05 EPS

Arcutis Biotherapeutics (NASDAQ:ARQT) announced its quarterly earnings data on Wednesday. The company reported $0.11 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.06 by $0.05, FiscalAI reports. Arcutis Biotherapeutics had a net margin of 6.15% and a return on equity of 15.93%. The business had revenue of $129.86 million for the quarter, compared to analysts’ expectations of $118.85 million.

Here are the key takeaways from Arcutis Biotherapeutics’ conference call:

• Positive Sentiment: Q2 net product revenue rose 59% year over year to $129.9 million, driven by strong ZORYVE demand and improved gross-to-net deductions. The company raised its full-year 2026 revenue guidance to $525 million–$540 million from $480 million–$495 million.
• Positive Sentiment: ZORYVE received FDA approval for plaque psoriasis in children as young as two, while the FDA accepted the application for atopic dermatitis in infants down to three months, with a February 2027 decision expected. Management views the pediatric indications as significant unmet-need opportunities.
• Positive Sentiment: Arcutis is investing in growth through expanded dermatology, primary-care and pediatric sales teams, direct-to-consumer marketing, a virtual dermatology platform and AI-enabled prescription fulfillment tools. The company expects the dermatology expansion to support second-half 2026 growth, with primary-care and pediatric contributions beginning in 2027.
• Positive Sentiment: The company reported $15 million of net income and $12.6 million of operating cash flow in Q2, ending the quarter with $238.9 million in cash and marketable securities. Management expects positive cash flow for the remainder of 2026 while continuing to fund pipeline and commercial investments.
• Negative Sentiment: Chief Commercial Officer Todd Edwards will leave later this month to pursue other opportunities, creating a leadership transition. Arcutis appointed Rob Lisicky as interim CCO while it conducts a permanent search, although management characterized the commercial team and transition plan as strong.

Arcutis Biotherapeutics Stock Down 2.5%

Arcutis Biotherapeutics stock opened at $26.43 on Friday. The firm has a market cap of $3.31 billion, a price-to-earnings ratio of 125.86 and a beta of 1.49. Arcutis Biotherapeutics has a 52-week low of $13.69 and a 52-week high of $31.77. The company has a debt-to-equity ratio of 0.54, a quick ratio of 2.46 and a current ratio of 2.68. The firm has a 50 day moving average price of $25.97 and a two-hundred day moving average price of $24.69.

Wall Street Analysts Forecast Growth

Several equities analysts recently commented on ARQT shares. Needham & Company LLC increased their price objective on shares of Arcutis Biotherapeutics from $36.00 to $40.00 and gave the company a “buy” rating in a research note on Thursday. Wall Street Zen upgraded shares of Arcutis Biotherapeutics from a “hold” rating to a “buy” rating in a report on Sunday, July 12th. Morgan Stanley increased their price target on Arcutis Biotherapeutics from $34.00 to $38.00 and gave the company an “overweight” rating in a research note on Thursday. Weiss Ratings restated a “sell (d-)” rating on shares of Arcutis Biotherapeutics in a research report on Wednesday, June 24th. Finally, Guggenheim increased their target price on Arcutis Biotherapeutics from $35.00 to $38.00 and gave the company a “buy” rating in a research report on Thursday. Six analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $35.57.

Arcutis Biotherapeutics News Summary

Here are the key news stories impacting Arcutis Biotherapeutics this week:

• Positive Sentiment: Strong second-quarter performance: Arcutis reported adjusted EPS of $0.11, above the $0.06–$0.09 analyst range, while revenue reached $129.9 million, a 59% year-over-year increase and 23% sequential gain. The results reflect continued demand for ZORYVE and marked a significant improvement from the prior-year loss. Arcutis second-quarter financial results
• Positive Sentiment: Higher full-year outlook: Management raised 2026 net product sales guidance to $525 million–$540 million and maintained positive operating cash flow, supporting the view that ZORYVE commercialization is progressing ahead of expectations. Arcutis 2026 guidance update
• Positive Sentiment: Expanded market opportunity: ZORYVE cream was approved for plaque psoriasis in children as young as two, while the FDA accepted an application covering infants with atopic dermatitis. A Phase 2 vitiligo study has also completed enrollment, with results expected in the fourth quarter. ZORYVE regulatory and pipeline update
• Positive Sentiment: Analyst support: Needham raised its price target from $36 to $40 and reiterated a Buy rating. HC Wainwright’s 2027 estimates show quarterly EPS rising from $0.08 in the first quarter to $0.48 in the fourth quarter, indicating expectations for continued earnings growth. Needham price-target report
• Neutral Sentiment: Leadership transition: Arcutis announced key commercial leadership changes. The move could improve execution, but investors may initially monitor the effect on ZORYVE sales momentum and organizational stability. Arcutis commercial leadership changes
• Neutral Sentiment: Insider selling was administrative: Three executives sold shares under pre-arranged Rule 10b5-1 plans to cover tax withholding on vested equity awards, limiting the bearish significance of the transactions.

Insider Activity

In other news, insider Todd Watanabe sold 4,375 shares of the stock in a transaction on Monday, August 3rd. The shares were sold at an average price of $26.12, for a total transaction of $114,275.00. Following the completion of the sale, the insider directly owned 717,203 shares in the company, valued at $18,733,342.36. This represents a 0.61% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Masaru Matsuda sold 1,230 shares of the business’s stock in a transaction on Monday, August 3rd. The shares were sold at an average price of $26.12, for a total transaction of $32,127.60. Following the completion of the transaction, the insider owned 126,171 shares in the company, valued at approximately $3,295,586.52. The trade was a 0.97% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last three months, insiders have sold 16,894 shares of company stock valued at $422,044. 9.40% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Arcutis Biotherapeutics

Several institutional investors and hedge funds have recently made changes to their positions in ARQT. AQR Capital Management LLC increased its stake in shares of Arcutis Biotherapeutics by 21.4% in the 1st quarter. AQR Capital Management LLC now owns 248,196 shares of the company’s stock valued at $3,882,000 after acquiring an additional 43,716 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in Arcutis Biotherapeutics by 3.0% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 71,417 shares of the company’s stock worth $1,118,000 after purchasing an additional 2,063 shares during the period. Creative Planning increased its stake in Arcutis Biotherapeutics by 8.2% in the second quarter. Creative Planning now owns 19,575 shares of the company’s stock valued at $274,000 after purchasing an additional 1,477 shares in the last quarter. JPMorgan Chase & Co. raised its holdings in shares of Arcutis Biotherapeutics by 1.0% during the second quarter. JPMorgan Chase & Co. now owns 548,789 shares of the company’s stock valued at $7,694,000 after purchasing an additional 5,407 shares during the period. Finally, Russell Investments Group Ltd. grew its stake in shares of Arcutis Biotherapeutics by 4,562.5% in the 2nd quarter. Russell Investments Group Ltd. now owns 11,190 shares of the company’s stock valued at $157,000 after buying an additional 10,950 shares during the period.

Arcutis Biotherapeutics Company Profile

Arcutis Biotherapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for immuno-inflammatory skin diseases. The company’s research and development efforts center on targeted treatments that address the underlying biology of conditions such as plaque psoriasis, atopic dermatitis, seborrheic dermatitis and vitiligo. Arcutis employs a precision-medicine approach to deliver topical therapies designed to improve efficacy and tolerability compared with existing treatment options.

In August 2022, Arcutis received U.S.